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Libman-Sacks endocarditis in patients with systemic lupus 
erythematosus with secondary antiphospholipid syndrome 
 
Abstract 
Background: Libman-Sacks endocarditis (LSE) is characterized by sterile lesions that 
commonly affect the aortic and mitral heart valves. Antiphospholipid syndrome (APS) and 
systemic lupus erythematosus (SLE) have been associated with LSE. Cardiac 
manifestations including LSE could be interrelated with other manifestations and early 
diagnosis could help in preventing further complications. 
Case presentation: Here, we report three cases of LSE in SLE patients with secondary 
APS. All patients presented with neurological manifestations and LSE was diagnosed by 
Transesophageal echocardiography (TEE). All three patients were treated for the 
underlying disease and also received anticoagulant therapy. 
Conclusion: In all patients with SLE and secondary APS, LSE should be considered if a 
patient manifests any evidence of neurologic involvement. 
Keywords: Systemic lupus erythematosus, Antiphospholipid syndrome, Libman-Sacks 
endocarditis 
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LSE is a sterile and verrucous vegetation around the heart valves (1-3). LSE is 
usually associated with autoimmune diseases especially SLE and APS (1, 2). LSE mostly 
affects mitral and aortic heart valves (2), which may cause thromboembolic 
cerebrovascular events, valvular regurgitation, and increased risk of infective endocarditis 
(2-4). Although APS and valvular involvements are not rare, and have mostly low clinical 
significance, they could cause severe complications. Secondary APS compared to primary 
APS also have higher rate of cardiac involvement, mostly due to the autoimmune causes 
related to the SLE (4). Here, we report three cases of LSE in patients with SLE and 
secondary APS diagnosed after presenting with neurological manifestations.   
 
Case presentation 
Case 1: A 39-year-old female with a history of stroke 7 months prior to admission, 
presented with right sided hemiparesis and aphasia. Her home medications include 
clopidogrel 75 mg daily, aspirin 81 mg daily and losartan 25 mg daily. She had consulted 
the rheumatology department due to complaints of periodic polyarthralgia and positive 
anticardiolipin antibody (Ab), lupus anticoagulant, beta2-glycoprotein Ab, antinuclear 
antibody (ANA), anti-dsDNA and low complement levels. Patient was admitted with the 
diagnosis of SLE and APS. Transesophageal echocardiography (TEE) showed bicuspid 
aortic valve leaflets with mild aortic stenosis (AS) and mild aortic insufficiency (AI) with 
two nonmobile  small masses (5x5 mm and 9x5 mm) on the tip of right cusp and non-
coronary cusp suggestive of non-bacterial thrombotic endocarditis (Libman-Sacks 
endocarditis) (figure 1a and b). 
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Figure 1.a Transesophageal echocardiography (TEE) 
showed two small vegetations on the tip of right cusp and 
non-coronary cusp of bicuspid aortic valve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1b. Transesophageal echocardiography (TEE) 
showed two small vegetations on the tip of right cusp and 
non-coronary cusp of bicuspid aortic valve. 
 
She was started on intravenous (IV) heparin and bridged 
to oral warfarin to achieve an international normalized ratio 
(INR) goal of 2-3. The patient was also treated with 
prednisolone 20 mg, azathioprine 50 mg three times daily 
and hydroxychloroquine 200 mg twice daily. The patient 
was stable during her hospital stay. She was discharged with 
warfarin 5 mg daily with INR goal of 2-3, prednisolone 7.5 
mg daily, azathioprine 50 mg three times daily and 
hydroxychloroquine 200 mg twice daily. At 1 year follow-
up, she was symptom free without any SLE flair-up or 
cardiovascular incident. Follow-up TEE was indicative of no 
vegetations.  
Case 2: A 52-year-old female with a history of SLE and 
APS for 17 years, diabetes mellitus and hypertension for 2 
years, two episodes of deep vein thrombosis and three 
episodes of pulmonary thromboembolism presented with a 
chief complaint of disorientation and delirium. The patient 
was taking prednisolone 15 mg daily, azathioprine 50 mg 
three times daily, hydroxychloroquine 200 mg twice daily, 
Aspirin 80 mg daily, losartan 25 mg twice daily, amlodipine 
5 mg daily, insulin and dabigatran 150 mg twice daily since 
last year due to a heparin induced thrombocytopenia and 
possible SLE-related severe thrombocytopenia. Dabigatran 
was discontinued due to non-adherence to therapy two weeks 
prior to admission. Brain magnetic resonance imaging (MRI) 
showed left posterior parietal infarction for possible Libman-
Sacks endocarditis given her prior history of SLE. TEE 
showed two nonmobile small sized masses on the tip of 
anterior (6x5 mm) and posterior (4x4 mm) mitral valve 
leaflets (MVLs) indicative of Libman-Sacks endocarditis 
(figure 2).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Transesophageal echocardiography (TEE) 
revealed a thickened mitral valve with two small 
vegetations on the tip of anterior (and posterior mitral 
valve leaflets. 
 
During her hospital stay the patient was treated with the 
abovementioned medication plus prednisolone 30 mg daily 
and dabigatran 150 mg twice daily. After a week, her clinical 
status improved and she was discharged with continuation of 
therapy. However, during the 1 year follow-up, she was 
admitted twice, once for an incident of disorientation and 
once due to SLE flair-up. Follow-up TEE was indicative of 
no vegetations. 
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Case 3: A 24-year-old male presented with seizure to the 
neurology department. The patient had no history of 
previous seizure or neurologic diseases. He reported a 
history of provoked deep vein thrombosis 3 years ago. Due 
to the hemolytic anemia and maculopapular rashes, he was 
suspected to have SLE and possible APS. Laboratory results 
showed positive ANA, anti-dsDNA, low complements and 
proteinuria. Kidney biopsy showed stage V lupus nephritis. 
Lupus anticoagulant and β2-glicoprotein Ab-IgG were also 
positive suggestive of APS. The patient received 
prednisolone 75 mg daily (1 mg/kg/d) and was a candidate 
for cyclophosphamide treatment. He was evaluated for 
dyspnea before treatment and transthoracic 
echocardiography showed thickening of MVLs tips. TEE 
showed two small fixed masses on MVLs suggestive of 
Libman-Sacks endocarditis without any mobile projections.  
The patient was therapeutically anticoagulated with 
warfarin and discharged on warfarin 5 mg daily with INR 
goal of 2-3, prednisolone 25 mg daily, hydroxychloroquine 
400 mg daily, aspirin 80 mg and losartan 25 mg twice a day. 
He received first dose of IV cyclophosphamide therapy with 
scheduled monthly injections for the next five months. 
Follow-up TEE was indicative of remnant vegetations but no 
valvular deterioration. 
 
 
Discussion 
The involvement of heart valves are common cardiac 
manifestations in primary or secondary APS including 
thickening, stenosis, regurgitation and vegetation of the 
valves. Up to 70% of APS patients have at least one valvular 
abnormality diagnosed on echocardiography such as 
thickening, stenosis, regurgitation, and vegetations; however, 
the most important abnormality is LSE, mostly in mitral and 
aortic valves (5).  
LSE is a strong risk factor for cerebrovascular events 
including stroke or transient ischemic attack, as well as, 
cognitive disability in SLE/APS. The involved valves would 
have dysfunction including regurgitation or stenosis and 
require valve surgery. These all together increase the 
mortality in SLE and APS patients (3).   
Studies have shown an increased rate of LSE in cases 
with longer disease duration, disease activity, positive anti-
cardiolipin antibodies, and or having antiphospholipid 
syndrome (6). Previous studies have reported an increased 
rate of cerebral embolism as the common complication of 
LSE in APS patients (7). APS can occur as a primary 
disorder or secondary to an underlying disease such as SLE 
or other systemic autoimmune diseases. Also, one study 
reported more severe valve dysfunction due to LSE in cases 
with secondary APS compared to APS alone (8). 
All four valves could be involved, but mitral valve 
followed by aortic valve is the most common valves. 
Libman-Sacks vegetations are usually located at the base, 
middle, or tip of leaflets, located on the atrial side of the 
mitral valve or arterial side of the aortic valve, they have 
variable sizes and shapes and heterogeneous echogenicity 
(9). Early detection of LSE can help in early proper therapy 
and prevention of further related complications. TTE and 
TEE are used for the diagnosis of LSE and should be 
considered in high risk patients including patients with 
recent or recurrent thromboembolic events, stroke, seizure or 
cognitive dysfunction (1, 3).  
The exact mechanism and proper treatment for LSE is 
not well-established. Treatment of the underlying disease is 
necessary, but there is no consensus on the efficacy of the 
glucocorticoid or cytotoxic efficacy on valvular involvement. 
However, in all patients with vegetation or significant 
valvular thickening as well as those with thromboembolic 
events, anticoagulation therapy should be initiated (9). On 
the other hand, studies have indicated than even on proper 
anticoagulation therapy, valvular involvement and LSE 
occur in APS and SLE patients (10). As one of our patients 
had LSE while being treated with rivaroxaban. Surgical 
treatment including replacement or repair should be 
considered for severe valve regurgitation and stenosis. 
In conclusion, we report that in all patients with SLE and 
secondary APS, TEE should be performed with any evidence 
of neurologic involvement for early diagnosis and proper 
treatment of LSE.  
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